BridgeMD
Avian influenza vaccine immunity
EU CTIS ID: 2023-509178-44-00
What this study is testing
The main objective of this study is to evaluate the humoral and cell-mediated immune responses induced by the customized avian influenza vaccine, specifically against the H5N1 2.3.4.4b clade.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18 to 65 years
- Belongs to the target group of the avian influenza vaccine
- Is planning to receive at least one dose of the avian influenza vaccine
- Is able to understand the given written and oral information
- Has given written informed consent
- Home address in Finland
You likely can't join if
- None
See the full eligibility criteria
- Age 18 to 65 years
- Belongs to the target group of the avian influenza vaccine
- Is planning to receive at least one dose of the avian influenza vaccine
- Is able to understand the given written and oral information
- Has given written informed consent
- Home address in Finland
- Is able to give samples 3 weeks after each vaccine dose and preferably also participate in the follow-up at 6 and 12 months
- Pregnant and lactating women can participate in the study
- None
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.